RYBIX ODT (tramadol hydrochloride) by Shionogi is tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. First approved in 2005.
Drug data last refreshed 16h ago · AI intelligence enriched 21h ago
RYBIX ODT is an orally disintegrating tablet formulation of tramadol hydrochloride, a synthetic opioid agonist approved in 2005 for pain management. The drug works through dual mechanism: binding to μ-opioid receptors and inhibiting reuptake of norepinephrine and serotonin, with analgesic onset within one hour and peak effect in 2-3 hours. Its active metabolite M1 is significantly more potent than the parent compound in opioid binding and analgesia.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team downsizing or transition to generic defense strategies.
tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to μ-opioid receptors and weak inhibition of re-uptake of norepinephrine and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain
Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets
Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
Worked on RYBIX ODT at Shionogi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
RYBIX ODT currently shows zero linked job openings, reflecting its LOE-approaching lifecycle stage and lack of active portfolio growth initiatives. Career opportunities on this product are limited to maintenance and transition roles focused on maximizing remaining exclusivity and managing generic entry.